Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to disclosure of share transactions and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details specific share transactions executed on June 30, 2015, involving the sale, repurchase, and transfer of Ordinary Shares by Sir Andrew Witty and his connected persons.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or strategic updates.
Key Facts for Investor Verification
- Director Sir Andrew Witty and connected persons executed sales and repurchases of Ordinary Shares on June 30, 2015.
- Transactions included transfers of 1,000 shares each to connected persons for nil consideration.
- Share prices for these transactions ranged approximately between 1337.82p and 1338.67p.
- The Company was advised of these transactions on July 1, 2015.
- This filing does not contain financial results; investors should refer to Form 20-F or quarterly reports for financial metrics.